Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: a phase I modified continual reassessment method study

@article{Kuzuya2001OptimalDO,
  title={Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: a phase I modified continual reassessment method study},
  author={Kazuo Kuzuya and Hirofumi Ishikawa and Toshimasa Nakanishi and Fumitaka Kikkawa and Akihiro Nawa and Hidetaka Fujimura and Akira Iwase and Yoshitaro Arii and Motoji Kawai and Sadao Hattori and Kanako Sakakibara and Emiko Sasayama and Yasuo Furuhashi and Takahiro Suzuki and Shigehiko Mizutani},
  journal={International Journal of Clinical Oncology},
  year={2001},
  volume={6},
  pages={271-278}
}
AbstractBackground. A multicenter, phase I study of combination therapy with paclitaxel and carboplatin for epithelial ovarian cancer was conducted to determine the safety and recommended dosages for Japanese women. Methods. Paclitaxel was administered intravenously over a 3-h period, followed by carboplatin administered intravenously over a 1.5-h period. A modified continual reassessment method (mCRM) was used in two treatment arms to establish the maximum tolerated dose (MTD) and recommended… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 21 REFERENCES

Determination of the optimal dose of paclitaxel (TAX) and carboplatin (CBDCA) for ovarian cancer (JKTB Group Study) (abstract 1456)

E Kimura, K Ochiai, M Yasuda
  • Proc Am Soc Clin Oncol 18:377a
  • 1999
VIEW 1 EXCERPT

Clinical pharmacology of carboplatin administered in combination with paclitaxel

LJ van Warmerdam, MT Huizing, G Giaccone
  • Semin Oncol 24(Suppl
  • 1997
VIEW 2 EXCERPTS

Is cisplatinpaclitaxel (P-T) the standard in first-line treatment of advanced ovarian cancer (Ov Ca)? The EORTC-GCCG, NOCOVA, NCI-C and Scottish Intergroup experience (abstract 1258

MJ Piccart, K Bertelsen, G Stuart
  • Proc Am Soc Clin Oncol
  • 1997
VIEW 1 EXCERPT

Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer

MT Huizing, LJC van Warmerdam, H Rosing
  • J Clin Oncol
  • 1997
VIEW 1 EXCERPT